Table 1 Characteristics of the patients in the study population
GEF | Control | ||
|---|---|---|---|
Sex | Male | 14(38%) | 28(78%) |
Female | 23(62%) | 8(22%) * | |
Age(year) | Median | 63 | 62 |
Range | 44–77 | 37–84 ** | |
Histrogy | Adeno | 36(97%) | 26(72%) |
Squamouse | 1(3%) | 7(19%) | |
other | 0(0%) | 3(8%) | |
EGFR mutation | L858R | 18(49%) | - |
19Del | 18(49%) | - | |
19DEL/L858R | 1(2%) | ||
Metastatic type | Osteolytic | 31(56%) | 30(57%) |
Mixed | 24(44%) | 21(40%) | |
Undetectable | 0(0%) | 2(4%) | |
Evaluated sites | Spine | 38(69%) | 35(66%) |
Pelvis | 8(15%) | 6(11%) | |
Femur | 3(5%) | 3(6%) | |
Other | 6(11%) | 9(17%) | |
Gefitinib (Days) | Median | 250 | - |
Range | 37–763 | - | |
Radiotherapy | + | 39(71%) | 31(58%) |
- | 16(29%) | 22(42%) | |
1-year overall survival | 80.0% | 35.3% *** |